Trial
NCT03494231
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Henlix, Inc
Collaborators
—
Condition
Solid Tumor, Adult
Intervention
HLX06
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-30